"The FDA continues to alert the public to potential safety and efficacy concerns with unapproved CBD products sold online and in stores across the country," said FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D.
"The opioid crisis continues to be a serious problem in the United States, and we will continue to crack down on companies that attempt to benefit from selling products with unfounded treatment claims," said FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D. The U.S. Food and Drug Administration has issued warning letters to two companies for illegally (...)